Fructosamine is a valuable marker for glycemic control and predicting adverse outcomes following total hip arthroplasty: a prospective multi-institutional investigation

• Published in: Scientific reports Vol. 11; no. 1; pp. 2227 - 8
• Main Authors: Shohat, Noam, Goswami, Karan, Breckenridge, Leigham, Held, Michael B., Malkani, Arthur L., Shah, Roshan P., Schwarzkopf, Ran, Parvizi, Javad
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.01.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/1537/805; 692/308; Arthroplasty (knee); Confidence intervals; Health risks; Hip; Humanities and Social Sciences; Joint diseases; Joint replacement surgery; Joint surgery; Morbidity; Mortality; Mortality risk; multidisciplinary; Patients; Regression analysis; Science; Science (multidisciplinary); Statistical analysis; Surgery; Total hip arthroplasty
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-81803-6

Recently, fructosamine has shown promising results in predicting adverse outcomes following total knee arthroplasty. The purpose of this study was to assess the utility of fructosamine to predict adverse outcomes following total hip arthroplasty (THA). A prospective multi-center study involving four institutions was conducted. All primary THA were evaluated for glycemic control using fructosamine levels prior to surgery. Adverse outcomes were assessed at a minimum 1 year from surgery. Primary outcome of interest was periprosthetic joint infection (PJI) based on the International Consensus Meeting (ICM) criteria. Secondary outcomes assessed were superficial infections, readmissions and death. Based on previous studies on the subject, fructosamine levels above 293 µmol/L were used to define inadequate glycemic control. Overall 1212 patients were enrolled in the present study and were available for follow up at a minimum 1 year from surgery. Of those, 54 patients (4.5%) had elevated fructosamine levels (> 293 µmol/L) and these patients were 6.7 times more likely to develop PJI compared to patients with fructosamine levels below 293 µmol/L (p = 0.002). Patients with elevated fructosamine were also associated with more readmissions (16.7% vs. 4.4%, p < 0.007) and a higher mortality rate (3.7% vs. 0.6%, p = 0.057). These associations remained statistically significant in a multi-regression analysis after adjusting for age, comorbidities and length of stay; Adjusted odds ratio were 6.37 (95% confidence interval 1.98–20.49, p = 0.002) for PJI and 2.68 (95% confidence interval 1.14–6.29, p = 0.023) for readmissions. Fructosamine is a good predictor of adverse outcomes in patients undergoing THA and should be used routinely to mitigate morbidity and mortality risk.